Abstract |
Oral administration for 6 days of 100 mg/kg MMK-1, an agonist peptide selective for the FPRL1 receptor, suppressed alopecia induced by the anticancer drug etoposide in neonatal rats. The anti- alopecia effect of orally administered MMK-1 was not inhibited by pyrilamine or cimetidine, antagonists for histamine H1 and H2 receptors, respectively, which blocked the anti- alopecia effect of intraperitoneally administered MMK-1 at a dose of 10 mg/kg for 4 days. However, the anti- alopecia effect of orally administered MMK-1 was inhibited by indomethacin, an inhibitor of cyclooxygenase (COX), or AH-23848B, an antagonist of the EP4 receptor for prostaglandin (PG) E2, suggesting involvement of PGE2 release and the EP4 receptor in the oral MMK-1 anti- alopecia mechanism. The anti- alopecia effect of orally administered MMK-1 was also blocked by an inhibitor of nuclear factor-kappaB ( NF-kappaB), pyrrolidine dithiocarbamate, suggesting that the oral anti- alopecia effect of MMK-1 may be mediated by activation of NF-kappaB. These results suggest that MMK-1 bound to FPRL1 receptor might suppress etoposide-induced apoptosis of hair follicle cells and alopecia by way of PGE2 release and NF-kappaB activation.
|
Authors | Takahiro Tsuruki, Masaaki Yoshikawa |
Journal | Peptides
(Peptides)
Vol. 27
Issue 4
Pg. 820-5
(Apr 2006)
ISSN: 0196-9781 [Print] United States |
PMID | 16183167
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- FPR2 protein, human
- MMK-1 peptide
- Peptides
- Receptors, Formyl Peptide
- Receptors, Lipoxin
- Etoposide
- Cimetidine
- Pyrilamine
- Indomethacin
|
Topics |
- Administration, Oral
- Alopecia
(chemically induced, drug therapy)
- Animals
- Cimetidine
(pharmacology)
- Disease Models, Animal
- Etoposide
(pharmacology)
- Female
- Indomethacin
(pharmacology)
- Injections, Intraperitoneal
- Male
- Peptides
(administration & dosage, pharmacology)
- Pyrilamine
(pharmacology)
- Rats
- Receptors, Formyl Peptide
(agonists)
- Receptors, Lipoxin
(agonists)
|